

ASX ANNOUNCEMENT**7 April 2022****ODC manufacture permit granted for Mildura**

7 April 2022 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) announced today that the Office of Drug Control (**ODC**) has granted Cann the necessary permit to allow the manufacture of medicinal cannabis products at its Mildura facility. Cann will utilise this permit for its extraction suite on site.

This permit was foreshadowed in an earlier announcement on 15 March 2022, regarding the issue of a permit to allow cultivation and production of medicinal cannabis and research activities in relation to medicinal cannabis. The manufacturing permit now completes the suite of ODC permits required for the operation of its Mildura facility.

Cann is also continuing to work with the Therapeutic Goods Administration on the GMP licence application for the Mildura site and Cann expects to have that licence in place in coming months.

The extracts that Cann will produce at the Mildura facility will be used to formulate medicinal cannabis products for Cann's customers for supply within Australia and overseas. Additionally, Cann is authorised to sell extracts as an Active Pharmaceutical Ingredient (**API**).

Cann's CEO, Mr Peter Crock, said "*The granting of this permit by the ODC is one of the last pieces of the puzzle for our Mildura facility. It is pleasing to see that all of the work that we have been doing on the site and with our regulators is now coming to fruition, and this will now enable us to get Australian manufactured products of the highest quality to our Australian and overseas customers.*"

Authorised for release by the Board of Directors, Cann Group Limited.

For all media enquiries please contact:

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

For all other information please contact:

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

Deborah Ambrosini
CFO
Cann Group Limited
+61 3 9095 7088
deborah.ambrosini@canngrouponlimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market a proprietary delivery system for cannabinoids. Cann has established research, cultivation and GMP manufacturing facilities in Melbourne and is finalising the construction of a state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products.

Learn more at: www.canngrouponlimited.com | www.satipharm.com